Zeneli A, Brandi G, Di Pasquale G, Orlandini D, De Carolis P, Bravi F, Pugliese F, Poluzzi E, Catena F, Giovanardi F, Valpiani G, Mantovani R, Magnanimi E, Iannone P., Identifying ethical values for guiding triage decisions during the COVID-19 pandemic: an Italian ethical committee perspective using Delphi methodology, «BMJ OPEN», 2021, 11, Article number: e043239 , pp. 1 - 10 [Scientific article]Open Access
Rizzo A.; Ricci A.D.; Brandi G., IDH inhibitors in advanced cholangiocarcinoma: Another arrow in the quiver?, «CANCER TREATMENT AND RESEARCH COMMUNICATIONS», 2021, 27, pp. 1 - 6 [Scientific article]Open Access
Rizzo A.; Ricci A.D.; Brandi G., Immune-based combinations for advanced hepatocellular carcinoma: Shaping the direction of first-line therapy, «FUTURE ONCOLOGY», 2021, 17, pp. 755 - 757 [Scientific article]
Rizzo A.; Ricci A.D.; Lanotte L.; Lombardi L.; Di Federico A.; Brandi G.; Gadaleta-Caldarola G., Immune-based combinations for metastatic triple negative breast cancer in clinical trials: current knowledge and therapeutic prospects, «EXPERT OPINION ON INVESTIGATIONAL DRUGS», 2021, 1, pp. 1-9 - 9 [Scientific article]
Ricci A.D.; Rizzo A.; Brandi G., In Regard to “A Phase Ib Study of NUC-1031 in Combination with Cisplatin for the First-Line Treatment of Patients with Advanced Biliary Tract Cancer (ABC-08)”, «THE ONCOLOGIST», 2021, 26, pp. e902 - e902 [Comment or similar]
Rizzo, A.; Frega, G.; Palloni, A.; Piemontese, A.; Di Federico, A.; Ricci, A.; Carloni, R.; Fabbri, F.; Novelli, M.; Tavolari, S.; Di Marco, M.; Ravaioli, M.; Brandi, G., Intensive follow-up program and oncological outcomes of 278 biliary tract cancer patients after curative intent surgery: A single-center retrospective experience, «ANNALS OF ONCOLOGY», 2021, 32, Article number: P-69 , pp. S120 - S120 [Scientific article]
Ravaioli M.; Piscaglia F.; Cillo U.; Brandi G.; Sessa M.; Germinario G.; Golfieri R.; Cappelli A.; Morelli M.C.; Siniscalchi A.; D'Errico A.; Cescon M.; Iannone P.; Trevisani F., Is the Strongest Level of Medical Evidence Always Required for Guidelines Recommendations?, «LIVER CANCER», 2021, 10, pp. 394 - 395 [Comment or similar]Open Access
Rizzo A.; Ricci A.D.; Brandi G., Ivosidenib in IDH-mutant cholangiocarcinoma: where do we stand?, «EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT», 2021, 6, pp. 217 - 224 [Scientific article]
Rizzo A.; Santoni M.; Mollica V.; Fiorentino M.; Brandi G.; Massari F., Microbiota and prostate cancer, «SEMINARS IN CANCER BIOLOGY», 2021, 1044, pp. 1 - 8 [Scientific article]
Rizzo A.; Brandi G., Neoadjuvant therapy for cholangiocarcinoma: A comprehensive literature review, «CANCER TREATMENT AND RESEARCH COMMUNICATIONS», 2021, 27, Article number: 100354 , pp. 100354 - 100360 [Scientific article]Open Access
Di Federico A.; Rizzo A.; Ricci A.D.; Frega G.; Palloni A.; Tavolari S.; Brandi G., Nivolumab: an investigational agent for the treatment of biliary tract cancer, «EXPERT OPINION ON INVESTIGATIONAL DRUGS», 2021, 30, pp. 325 - 332 [Scientific article]
Rizzo A.; Brandi G., Novel targeted therapies for advanced cholangiocarcinoma, «MEDICINA», 2021, 57, Article number: 212 , pp. 1 - 3 [Scientific article]Open Access
Rizzo A.; Ricci A.D.; Brandi G., Pd‐l1, tmb, msi, and other predictors of response to immune checkpoint inhibitors in biliary tract cancer, «CANCERS», 2021, 13, Article number: 558 , pp. 1 - 11 [Scientific article]Open Access
Rizzo A.; Ricci A.D.; Brandi G., Pemigatinib: Hot topics behind the first approval of a targeted therapy in cholangiocarcinoma, «CANCER TREATMENT AND RESEARCH COMMUNICATIONS», 2021, 27, pp. 1 - 6 [Scientific article]Open Access
Rizzo A.; Brandi G., Pitfalls, challenges, and updates in adjuvant systemic treatment for resected biliary tract cancer, «EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY», 2021, 15, pp. 547 - 554 [Scientific article]
